<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05077280</url>
  </required_header>
  <id_info>
    <org_study_id>2021.072-2</org_study_id>
    <nct_id>NCT05077280</nct_id>
  </id_info>
  <brief_title>A Study of Concurrent Stereotactic Body Radiotherapy With Ipi and Nivo in Metastatic Uveal Melanoma</brief_title>
  <official_title>A Phase II Study of Concurrent Stereotactic Body Radiotherapy With Ipilimumab and Nivolumab in Patients With Metastatic Uveal Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>California Pacific Medical Center Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>California Pacific Medical Center Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2 trial of concurrent stereotactic radiation therapy (SBRT) with&#xD;
      immunotherapy with ipilimumab and nivolumab for up to two years. SBRT will be given in three&#xD;
      doses of 15Gy each to 1-5 separate metastases. Ipilimumab will be given at 1mg/kg q 6 weeks&#xD;
      for 12 doses, and nivolumab will be given 360mg every 3 weeks for 2-3 years.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Metastatic uveal melanoma has no standard therapy, but there is evidence that both radiation&#xD;
      therapy and immunotherapy may be helpful and may be synergistic. This is a phase 2 trial of&#xD;
      concurrent stereotactic radiation therapy (SBRT) with immunotherapy with ipilimumab and&#xD;
      nivolumab for up to two years. SBRT will be given in three doses of 15Gy each to 1-5 separate&#xD;
      metastases, limiting the total dosage to 700cc's of normal liver to &lt;15Gy. Ipilimumab will be&#xD;
      given at 1mg/kg q 6 weeks for 12 doses, and nivolumab will be given 360mg every 3 weeks for&#xD;
      2-3 years. Objectives are to determine the safety and tolerability, and iRECIST will be used&#xD;
      to determine responses.We will treat up to 50 patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 20, 2021</start_date>
  <completion_date type="Anticipated">March 2026</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety and tolerability of the therapy</measure>
    <time_frame>5 years</time_frame>
    <description>toxicity measured by CTAE graded 3-5 toxicities</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>5 years</time_frame>
    <description>iRECIST defined response rates</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>5 years</time_frame>
    <description>survival without progressive cancer</description>
  </other_outcome>
  <other_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>survival</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Uveal Melanoma</condition>
  <arm_group>
    <arm_group_label>one arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>see below</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>stereotactic body radiotherapy</intervention_name>
    <description>Stereotactic Body radiotherapy will be given to 1-5 target metastases in 3 doses over 8 days or less. Each dose will be 15Gy for a total dose of 45GY</description>
    <arm_group_label>one arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immunotherapy</intervention_name>
    <description>Ipilimumab 1mg/kg every 6 weeks for 12 doses &amp; nivolumab 360mg every 3 weeks for 2-3 years</description>
    <arm_group_label>one arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  measurable metastatic uveal melanoma.&#xD;
&#xD;
          -  No concomitant therapy.&#xD;
&#xD;
          -  Prior PD1 or tebendafesp allowed.&#xD;
&#xD;
          -  Performance status 0-1.&#xD;
&#xD;
          -  No active Hepatitis B.&#xD;
&#xD;
          -  No known HIV infection.&#xD;
&#xD;
          -  WBC&gt;2000, ANC&gt;1500, Hgb &gt;8.&#xD;
&#xD;
          -  Creatinine &lt; 3 x ULN.&#xD;
&#xD;
          -  AST &amp; ALT &lt; 2.5 x ULN Bilirubin &lt; 2 x ULN.&#xD;
&#xD;
          -  Albumin &gt;2.9&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Liver tumor volume &gt; 50%.&#xD;
&#xD;
          -  Active CNS metastases.&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Prior therapy with ipilimumab or other CTLA-4 inhibitor.&#xD;
&#xD;
          -  Certain autoimmune diseases.&#xD;
&#xD;
          -  Previous liver embolization or radiation.&#xD;
&#xD;
          -  Use of systemic steroids&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David R Minor, MD</last_name>
    <role>Study Chair</role>
    <affiliation>California Pacific Med Center Research Inst.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Madeline Decker</last_name>
    <phone>4156006000</phone>
    <email>KimKB@sutterhealth.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>California Pacific Medical Center Research Institute</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Madeline Decker</last_name>
      <phone>415-600-3613</phone>
      <email>KimB@sutterhealth.org</email>
    </contact>
    <investigator>
      <last_name>Kevin B Kim, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 5, 2021</study_first_submitted>
  <study_first_submitted_qc>October 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2021</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Uveal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

